Anavex Life Sciences Corp (AVXL)

[toemind]

Regarding the schizophrenia trial from clinicaltrials.gov:
Looks like the formal end of study is May 15th, 2025.
Who knows what the specifics will be within that time frame.
ToeMind

"Detailed Description:
ANAVEX3-71-SZ-001 is a two-part study. The first part is Part A: Multiple Ascending Dose, PK, safety, and dose selection. The second part is Part B: Double Blind, Placebo Controlled for exploratory efficacy and continued repeat-dose safety. This study will investigate the effects of ANAVEX3-71 in patients with Schizophrenia for the first time. This is an in-patient study. In both parts, participants will undergo either 10 or 28 days of dosing (Part A and Part B, respectively). Standard clinical outcome measures used in the clinic and novel fluid and electrophysiological biomarkers will also be assessed.
Study Design
Go to

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment in Part A and Part B.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)
Actual Study Start Date : March 15, 2024
Estimated Primary Completion Date : May 15, 2025
Estimated Study Completion Date : May 15, 2025"

https://classic.clinicaltrials.gov/ct2/show/NCT06245213